# Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

> **NCT04268706** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tessa Therapeutics** · enrollment: 97 (estimated)

## Conditions studied

- Hodgkin Lymphoma, Adult
- Hodgkin Disease Recurrent
- Hodgkin Disease Refractory
- Hodgkin Disease, Pediatric

## Interventions

- **DRUG:** CD30.CAR-T
- **DRUG:** Fludarabine
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04268706
- **Lead sponsor:** Tessa Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-01
- **Primary completion:** 2025-05
- **Final completion:** 2037-03
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268706, "Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04268706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*